NYSE:DNA Ginkgo Bioworks (DNA) Stock Price, News & Analysis $11.24 -1.50 (-11.77%) Closing price 10/30/2026 03:59 PM EasternExtended Trading$11.18 -0.05 (-0.49%) As of 10/30/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ginkgo Bioworks Stock (NYSE:DNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ginkgo Bioworks alerts:Sign Up Key Stats Today's Range$10.60▼$12.6550-Day Range$6.75▼$15.0652-Week Range$5.37▼$18.22Volume2.73 million shsAverage Volume3.50 million shsMarket Capitalization$756.90 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingReduce Company Overview Ginkgo Bioworks is a biotechnology company that develops and deploys biological systems for commercial and industrial applications. Its platform is designed to help customers program cells to produce a wide range of products, including pharmaceuticals, food ingredients, agricultural inputs, specialty chemicals and materials. The company combines biological engineering, automation, software and data science to design, build and test engineered organisms. Ginkgo provides services through its cell-programming platform and biological engineering foundry, supporting activities such as genetic design, strain construction, laboratory testing and process development. It also develops organism and genetic engineering capabilities for applications in areas including biopharmaceuticals, consumer products, agriculture, industrial biotechnology and biosecurity. Ginkgo Bioworks was founded in 2008 by Jason Kelly, Reshma Shetty, Barry Canton, Austin Che and Tom Knight. The company became publicly traded on the New York Stock Exchange in 2021 through a business combination with Soaring Eagle Acquisition Corp. Jason Kelly is a co-founder and has served as the company's chief executive officer. Ginkgo works with customers and partners across multiple industries and geographic markets.AI Generated. May Contain Errors. Read More Ginkgo Bioworks Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreDNA MarketRank™: 1.010825616275 of 5 starsGinkgo Bioworks scored higher than 20% of companies evaluated by MarketBeat, and ranked 823rd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.6 / 5Analyst RatingReduce Consensus RatingGinkgo Bioworks has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 2 sell ratings.Downside RiskGinkgo Bioworks has a consensus price target of $7.00, representing about 37.7% downside from its current price of $11.24.Amount of Analyst CoverageGinkgo Bioworks has only been the subject of 4 research reports in the past 90 days.Read more about Ginkgo Bioworks' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ginkgo Bioworks are expected to grow in the coming year, from ($3.20) to ($2.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ginkgo Bioworks is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ginkgo Bioworks is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGinkgo Bioworks has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ginkgo Bioworks' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.11% of the float of Ginkgo Bioworks has been sold short.Short Interest Ratio / Days to CoverGinkgo Bioworks has a short interest ratio ("days to cover") of 1.88, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ginkgo Bioworks has recently increased by 13.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGinkgo Bioworks does not currently pay a dividend.Dividend GrowthGinkgo Bioworks does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.20 News SentimentGinkgo Bioworks has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Ginkgo Bioworks this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for DNA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows9 people have added Ginkgo Bioworks to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ginkgo Bioworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,379,699.00 in company stock.Percentage Held by Insiders12.69% of the stock of Ginkgo Bioworks is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.63% of the stock of Ginkgo Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ginkgo Bioworks' insider trading history. Receive DNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNA Stock News HeadlinesGinkgo Bioworks (NYSE:DNA) Shares Down 11.7% - Here's WhyNovember 1 at 4:01 AM | americanbankingnews.comGinkgo Bioworks : Announces Date of Third Quarter 2026 Results PresentationOctober 29 at 11:24 PM | marketscreener.comMThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 1 at 1:00 AM | Porter & Company (Ad)Ginkgo Bioworks Holdings consensus price target raised 14.29% to $8.16October 23, 2026 | msn.comGinkgo Bioworks (NYSE:DNA) Stock: Insider Jason Kelly Sells 45,682 SharesOctober 23, 2026 | americanbankingnews.comConsensus price target for Ginkgo Bioworks Holdings raised 41.80% to MX$95.38October 22, 2026 | msn.comGinkgo Bioworks (NYSE:DNA) Insider Jason Kelly Sells 45,682 Shares of StockOctober 22, 2026 | insidertrades.comInsider Selling: Ginkgo Bioworks (NYSE:DNA) Insider Sells 2,403 Shares of Company StockOctober 8, 2026 | insidertrades.comSee More Headlines DNA Stock Analysis - Frequently Asked Questions How have DNA shares performed this year? Ginkgo Bioworks' stock was trading at $8.27 on January 1st, 2026. Since then, DNA stock has increased by 35.9% and is now trading at $11.24. How were Ginkgo Bioworks' earnings last quarter? Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) released its earnings results on Wednesday, August, 5th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.15. The firm had revenue of $20.16 million for the quarter, compared to analysts' expectations of $24.05 million. Ginkgo Bioworks had a negative net margin of 259.96% and a negative trailing twelve-month return on equity of 60.27%. Read the conference call transcript. Who are Ginkgo Bioworks' major shareholders? Top institutional investors of Ginkgo Bioworks include Forbes J M & Co. LLP (1.45%), Prescott Group Capital Management L.L.C. (0.52%) and Q Fund Management Hong Kong Ltd (0.06%). Insiders that own company stock include Marijn E Dekkers, Mark E Dmytruk, Harry Sloan, Reshma P Shetty, Barry Canton, Jason R Kelly, Steven P Coen and Christian O Henry. View institutional ownership trends. How do I buy shares of Ginkgo Bioworks? Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ginkgo Bioworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ginkgo Bioworks investors own include Tesla (TSLA), Palantir Technologies (PLTR), SoFi Technologies (SOFI), NVIDIA (NVDA), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP) and Plug Power (PLUG). Company Calendar Last Earnings8/05/2026Today11/01/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 DNA's financial health is in the Green zone, according to TradeSmith. DNA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:DNA CIK1830214 Webwww.ginkgobioworks.com Phone877-442-5362FaxN/AEmployees485Year Founded2020Price Target and Rating Average Price Target for Ginkgo Bioworks$7.00 High Price Target$11.00 Low Price Target$5.00 Potential Upside/Downside-37.7%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($5.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$312.76 million Net Margins-259.96% Pretax Margin-277.33% Return on Equity-60.27% Return on Assets-26.88% Debt Debt-to-Equity RatioN/A Current Ratio4.57 Quick Ratio4.57 Sales & Book Value Annual Sales$170.15 million Price / Sales4.45 Cash FlowN/A Price / Cash FlowN/A Book Value$8.74 per share Price / Book1.29Miscellaneous Outstanding Shares67,340,000Free Float58,795,000Market Cap$756.90 million OptionableOptionable Beta1.79 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:DNA) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
